Legal
What’s the FTC’s Problem with Pay for Delay?
This week the Supreme Court heard arguments on the matter of pay-for-delay settlements between patent holders and generic firms. The Federal Trade Commission (FTC) hopes to overturn the 11th federal circuit’s ruling that such settlements are not anti-competitive. But what exactly is the FTC so worried about? ...Read more
Legal
Pay for Delay: Not in Pharma’s Best Interests
Traci Medford-Rosow and Peter C. Richardson spent over 30 years of their professional lives working for Big Pharma, many as Chief IP Counsels defending patents. Here, they explain why they believe that pay-for-delay provisions are not in the best interests of the research-based industry ...Read More
Digital Pharma
Social Media Guidelines: In Pursuit of a Policy
You don’t have a social media policy yet? Oh, you do, you just didn’t tell your staff? Peter Houston takes a cross-industry look at the faltering progress of social media guidelines and finds that pharma isn’t doing any worse in this area than other business sectors ...Read more
Global
Healthcare Systems in Europe “Failing Patients”
Any complacency that the world of healthcare might be feeling about advances in the ability to treat patients suffered a head-on assault at a conference in Dublin, Ireland, when one highly articulate cancer patient took the European healthcare to task ...Read more
Global
Read the Latest Pharm Exec Global Digest
In this month’s issue: Seeing through EU Pricing Transparency; Global Patent Management Made Easy; Multichannel Pharma Marketing; Harnessing Positive Content for Reputation Management ...Read more
|
